Pharmacovigilance,
Edition 2 A Practical ApproachEditors: Edited by Thao Doan, MD, Fabio Lievano, MD, PhD H.C., Linda Scarazzini, MD, Charles Schubert, MD, MPH and Barbara Hendrickson, MD
Conformance
-
PDF/UA-1
-
The publication was certified on 20250728
-
For detailed accessibility information, see Elsevier’s website at https://www.elsevier.com/about/accessibility
-
For queries regarding accessibility information, contact [email protected]
Ways Of Reading
-
This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation.
Navigation
-
The contents of the PDF have been tagged to permit access by assistive technologies as per PDF-UA-1 standard.
-
Page breaks included from the original print source
Additional Accessibility Information
-
The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.
-
For readers with color vision deficiency, use of color (e.g., in diagrams, graphics and charts, in prompts, or on buttons inviting a response) is not the sole means of graphical distinction or of conveying information
Note
-
This product relies on 3rd party tooling which may impact the accessibility features visible in inspection copies. All accessibility features mentioned would be present in the purchased version of the title.
Description
**Selected for 2026 Doody's Core Titles in Pharmacy**Written by multidisciplinary experts in the fields of pharmaceutical and patient safety, Pharmacovigilance: A Practical Approach, Second Edition, provides a succinct, easy-to-digest overview of an increasingly critical area of medical safety. From cover to cover, this concise resource offers essential information for physicians and other health care professionals, clinical researchers, and regulators who need a comprehensive, up-to-date source of information on the principles and practice of pharmacovigilance.
Key Features
- Presents vital, easy-to-read, cutting-edge information on patient safety, the pharmacology regulatory landscape, and the current and future use of digital technologies
- Provides up-to-date coverage of hot topics in the field, including pharmacodynamic and safety precision medicine, immunogenicity, vaccine hesitancy and safety, genetic toxicology, and adverse events
- Contains new chapters on pre-clinical safety assessment, pharmacogenetics, first-in human trials, product aggregate safety assessment, data monitoring committees, and more
- Offers new and expanded coverage of pharmacovigilance in early pre-clinical drug development through post-marketing surveillance, as well as a blueprint for training future pharmacovigilance professionals
- Includes real-world case studies to ensure content is relevant and applicable to everyday practice
- Discusses a range of topics across disciplines and how they relate to pharmacovigilance, including behavioral science, patient perspectives, and risk communication
- An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date
About the author
Edited by Thao Doan, MD, Group Medical Director, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Fabio Lievano, MD, PhD H.C., Vice President, Patient Safety, Scientific Collaborations, and New Business Advancement, Pharmacovigilance and Patient Safety, Epidemiology and, R&D Quality Assurance, AbbVie, North Chicago, IL, United States; Adjunct Faculty, Loyola University Stritch School of Medicine, Maywood, IL, United States; Adjunct Faculty, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Linda Scarazzini, MD, Senior Vice President, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, Chief Safety Officer, AbbVie, North Chicago, IL, USA; Charles Schubert, MD, MPH, Former Vice President, Oncology, Pharmacovigilance and Patient Safety, Epidemiology and R&D Quality Assurance, AbbVie, North Chicago, IL, USA and Barbara Hendrickson, MD, Clinical Associate, Department of Pediatrics, University of Chicago, Chicago, IL, USA
1. Does Regulation Drive Science or Does Science Drive Regulation?
SECTION 2 PRECLINICAL SAFETY ASSESSMENT
2. Absorption, Distribution, Metabolism and Excretion, Pharmacokinetics, and Safety Pharmacology
3. Preclinical Safety Assessment : General and Genetic Toxicology
4. Pharmacogenetics
SECTION 3 FIRST-IN-HUMAN TRIALS
5. Safety Planning for First-in-Human Trials
6. Pharmacokinetic and Pharmacodynamic Considerations in Safety Evaluation
SECTION 4 SAFETY ASSESSMENT IN CLINICAL TRIALS
7. Safety Monitoring in Clinical Trials
8. Introduction to Quantitative Methods and Visual Analytics in Drug Safety Data in Clinical Trials
9. Product Aggregate Safety Assessment
10. Data Monitoring Committees
SECTION 5 SIGNAL AND RISK MANAGEMENT
11. Methods of Signal Detection and Signal Management
12. Causality Assessment
13. Examples of Adverse Drug Reactions: Drug-Induced Liver Injury, Renal, Skin, Immune-Mediated Events, and Major Adverse Cardiac Events
14. Internal Safety Advisory Groups
15. Benefit–Risk Management
SECTION 6 ROLE OF EPIDEMIOLOGY AND REALWORLD EVIDENCE
16. Role of Epidemiology and Pharmacoepidemiology in the Biopharmaceutical Industry
17. Real-World Pharmacoepidemiology Studies
SECTION 7 SPECIAL POPULATIONS AND SPECIAL TOPICS
18. Pharmacovigilance in Pregnancy
19. Pharmacovigilance in Pediatrics
20. Pharmacovigilance in the Elderly
21. Vaccine Pharmacovigilance
22. Application of Human Factors and Health Literacy in Pharmacovigilance
23. Medical Device Safety Oversight and Surveillance
SECTION 8 THE NEXT FRONTIER
24. Information Technology in Pharmacovigilance: Current State and Future Directions
25. The Future of Pharmacovigilance